Incidence of adverse events in patients with metastatic breast cancer during use of standard and on/off capecitabine protocols

Detalhes bibliográficos
Autor(a) principal: Pestana, Isabela de Pinho
Data de Publicação: 2022
Outros Autores: Brasileiro, Luana do Amaral, Silveira, Alan Barbosa da, Oliveira, Livia Costa de
Tipo de documento: Artigo
Idioma: por
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/30426
Resumo: Capecitabine is a chemotherapy drug widely used in the treatment of metastatic breast cancer. Despite the clinical benefits, adverse events can influence the continuity of therapy. The on/off protocol was designed with the intention of optimizing treatment with capecitabine due to a likely reduction in adverse events. Thus, the aim of the study was to describe the incidence of adverse events during the use of standard and on/off capecitabine protocols. A retrospective cohort study was carried out, in which 221 patients with metastatic breast cancer were analyzed. The sample was divided into groups and subgroups: A - standard; B - on/off; A1 and B1 reduced dose; A2 and B2 full dose. The adverse event with the highest overall incidence (84%) was palmar-plantar erythrodysesthesia syndrome. Most adverse events showed no statistically significant variation in incidence between groups A and B. A higher incidence of adverse events was observed in patients who underwent full dose in both protocols. Regarding severity, most were classified as grade 1 and there was no statistical difference between groups A and B. The study suggests that switching from standard protocol to on/off, with the aim of reducing the incidence and severity of adverse events, does not have a significant impact. Dose reduction is a viable alternative to decrease the incidence of adverse reactions and is clinically relevant in some cases.
id UNIFEI_34b27cecf050b9170c5b22ab51bd5f4a
oai_identifier_str oai:ojs.pkp.sfu.ca:article/30426
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Incidence of adverse events in patients with metastatic breast cancer during use of standard and on/off capecitabine protocolsIncidencia de eventos adversos en pacientes con cáncer de mama metastásico durante el uso de protocolos estándar y on/off de capecitabinaIncidência de eventos adversos em pacientes com câncer de mama metastático durante uso dos protocolos padrão e on/off de capecitabinaBreast neoplasmsCapecitabineDrug-related side effects and adverse reactionsPharmaceutical care.Neoplasias da mamaCapecitabinaEfeitos colaterais e reações adversas relacionados a medicamentosAssistência farmacêutica.Neoplasias de mamaCapecitabinaEfectos secundarios y reacciones adversas relacionados con los medicamentosCuidado farmacéutico.Capecitabine is a chemotherapy drug widely used in the treatment of metastatic breast cancer. Despite the clinical benefits, adverse events can influence the continuity of therapy. The on/off protocol was designed with the intention of optimizing treatment with capecitabine due to a likely reduction in adverse events. Thus, the aim of the study was to describe the incidence of adverse events during the use of standard and on/off capecitabine protocols. A retrospective cohort study was carried out, in which 221 patients with metastatic breast cancer were analyzed. The sample was divided into groups and subgroups: A - standard; B - on/off; A1 and B1 reduced dose; A2 and B2 full dose. The adverse event with the highest overall incidence (84%) was palmar-plantar erythrodysesthesia syndrome. Most adverse events showed no statistically significant variation in incidence between groups A and B. A higher incidence of adverse events was observed in patients who underwent full dose in both protocols. Regarding severity, most were classified as grade 1 and there was no statistical difference between groups A and B. The study suggests that switching from standard protocol to on/off, with the aim of reducing the incidence and severity of adverse events, does not have a significant impact. Dose reduction is a viable alternative to decrease the incidence of adverse reactions and is clinically relevant in some cases.La capecitabina es un fármaco de quimioterapia ampliamente utilizado en el tratamiento del cáncer de mama metastásico. A pesar de los beneficios clínicos, los eventos adversos pueden influir en la continuidad de la terapia. El protocolo on/off se diseñó con la intención de optimizar el tratamiento con capecitabina debido a una probable reducción de los eventos adversos. Por lo tanto, el objetivo del estudio fue describir la incidencia de eventos adversos durante el uso de protocolos estándar y on/off de capecitabina. Se realizó un estudio de cohortes retrospectivo, en el que se analizaron 221 pacientes con cáncer de mama metastásico. La muestra fue dividida en grupos y subgrupos: A - estándar; B - encendido/apagado; A1 y B1 dosis reducida; A2 y B2 dosis completa. El evento adverso con mayor incidencia global (84%) fue el síndrome de eritrodisestesia palmar-plantar. La mayoría de los eventos adversos no mostraron una variación estadísticamente significativa en la incidencia entre los grupos A y B. Se observó una mayor incidencia de eventos adversos en los pacientes que recibieron la dosis completa en ambos protocolos. En cuanto a la gravedad, la mayoría se clasificó como grado 1 y no hubo diferencia estadística entre los grupos A y B. El estudio sugiere que el cambio del protocolo estándar a on/off, con el objetivo de reducir la incidencia y la gravedad de los eventos adversos, no tiene un impacto significativo. La reducción de dosis es una alternativa viable para disminuir la incidencia de reacciones adversas y es clínicamente relevante en algunos casos.A capecitabina é um quimioterápico amplamente utilizado no tratamento do câncer de mama metastático. Apesar dos benefícios clínicos, eventos adversos podem influenciar a continuidade da terapia. O protocolo on/off foi desenhado com a intenção de otimizar o tratamento com capecitabina devido a uma provável redução de eventos adversos. Com isso, o objetivo do estudo foi descrever a incidência dos eventos adversos durante uso dos protocolos padrão e on/off de capecitabina. Realizou-se um estudo de coorte retrospectivo, onde foram analisadas 221 pacientes com câncer de mama metastático. A amostra foi dividida em grupos e subgrupos: A - padrão; B - on/off; A1 e B1 dose reduzida; A2 e B2 dose plena. O evento adverso de maior incidência geral (84%) foi a síndrome de eritrodisestesia palmar-plantar. A maioria dos eventos adversos não apresentou variação estatisticamente significativa em relação à incidência entre os grupos A e B. Foi observado maior incidência de eventos adversos nos pacientes que realizaram dose plena em ambos os protocolos. Acerca da gravidade, a maioria foi classificada como grau 1 e não houve diferença estatística entre os grupos A e B. O estudo sugere que a troca de protocolo padrão para o on/off, com o objetivo de reduzir incidência e gravidade dos eventos adversos, não apresenta impacto significativo. Redução da dose é uma alternativa viável para diminuir a incidência de reações adversas sendo clinicamente relevante em alguns casos.Research, Society and Development2022-06-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/3042610.33448/rsd-v11i8.30426Research, Society and Development; Vol. 11 No. 8; e3711830426Research, Society and Development; Vol. 11 Núm. 8; e3711830426Research, Society and Development; v. 11 n. 8; e37118304262525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/30426/26249Copyright (c) 2022 Isabela de Pinho Pestana; Luana do Amaral Brasileiro; Alan Barbosa da Silveira; Livia Costa de Oliveirahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessPestana, Isabela de Pinho Brasileiro, Luana do Amaral Silveira, Alan Barbosa da Oliveira, Livia Costa de 2022-07-01T13:34:06Zoai:ojs.pkp.sfu.ca:article/30426Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:47:11.047918Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Incidence of adverse events in patients with metastatic breast cancer during use of standard and on/off capecitabine protocols
Incidencia de eventos adversos en pacientes con cáncer de mama metastásico durante el uso de protocolos estándar y on/off de capecitabina
Incidência de eventos adversos em pacientes com câncer de mama metastático durante uso dos protocolos padrão e on/off de capecitabina
title Incidence of adverse events in patients with metastatic breast cancer during use of standard and on/off capecitabine protocols
spellingShingle Incidence of adverse events in patients with metastatic breast cancer during use of standard and on/off capecitabine protocols
Pestana, Isabela de Pinho
Breast neoplasms
Capecitabine
Drug-related side effects and adverse reactions
Pharmaceutical care.
Neoplasias da mama
Capecitabina
Efeitos colaterais e reações adversas relacionados a medicamentos
Assistência farmacêutica.
Neoplasias de mama
Capecitabina
Efectos secundarios y reacciones adversas relacionados con los medicamentos
Cuidado farmacéutico.
title_short Incidence of adverse events in patients with metastatic breast cancer during use of standard and on/off capecitabine protocols
title_full Incidence of adverse events in patients with metastatic breast cancer during use of standard and on/off capecitabine protocols
title_fullStr Incidence of adverse events in patients with metastatic breast cancer during use of standard and on/off capecitabine protocols
title_full_unstemmed Incidence of adverse events in patients with metastatic breast cancer during use of standard and on/off capecitabine protocols
title_sort Incidence of adverse events in patients with metastatic breast cancer during use of standard and on/off capecitabine protocols
author Pestana, Isabela de Pinho
author_facet Pestana, Isabela de Pinho
Brasileiro, Luana do Amaral
Silveira, Alan Barbosa da
Oliveira, Livia Costa de
author_role author
author2 Brasileiro, Luana do Amaral
Silveira, Alan Barbosa da
Oliveira, Livia Costa de
author2_role author
author
author
dc.contributor.author.fl_str_mv Pestana, Isabela de Pinho
Brasileiro, Luana do Amaral
Silveira, Alan Barbosa da
Oliveira, Livia Costa de
dc.subject.por.fl_str_mv Breast neoplasms
Capecitabine
Drug-related side effects and adverse reactions
Pharmaceutical care.
Neoplasias da mama
Capecitabina
Efeitos colaterais e reações adversas relacionados a medicamentos
Assistência farmacêutica.
Neoplasias de mama
Capecitabina
Efectos secundarios y reacciones adversas relacionados con los medicamentos
Cuidado farmacéutico.
topic Breast neoplasms
Capecitabine
Drug-related side effects and adverse reactions
Pharmaceutical care.
Neoplasias da mama
Capecitabina
Efeitos colaterais e reações adversas relacionados a medicamentos
Assistência farmacêutica.
Neoplasias de mama
Capecitabina
Efectos secundarios y reacciones adversas relacionados con los medicamentos
Cuidado farmacéutico.
description Capecitabine is a chemotherapy drug widely used in the treatment of metastatic breast cancer. Despite the clinical benefits, adverse events can influence the continuity of therapy. The on/off protocol was designed with the intention of optimizing treatment with capecitabine due to a likely reduction in adverse events. Thus, the aim of the study was to describe the incidence of adverse events during the use of standard and on/off capecitabine protocols. A retrospective cohort study was carried out, in which 221 patients with metastatic breast cancer were analyzed. The sample was divided into groups and subgroups: A - standard; B - on/off; A1 and B1 reduced dose; A2 and B2 full dose. The adverse event with the highest overall incidence (84%) was palmar-plantar erythrodysesthesia syndrome. Most adverse events showed no statistically significant variation in incidence between groups A and B. A higher incidence of adverse events was observed in patients who underwent full dose in both protocols. Regarding severity, most were classified as grade 1 and there was no statistical difference between groups A and B. The study suggests that switching from standard protocol to on/off, with the aim of reducing the incidence and severity of adverse events, does not have a significant impact. Dose reduction is a viable alternative to decrease the incidence of adverse reactions and is clinically relevant in some cases.
publishDate 2022
dc.date.none.fl_str_mv 2022-06-07
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/30426
10.33448/rsd-v11i8.30426
url https://rsdjournal.org/index.php/rsd/article/view/30426
identifier_str_mv 10.33448/rsd-v11i8.30426
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/30426/26249
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 11 No. 8; e3711830426
Research, Society and Development; Vol. 11 Núm. 8; e3711830426
Research, Society and Development; v. 11 n. 8; e3711830426
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052767234162688